Larimar Therapeutics, Inc. 8-K

What Happened

• Larimar Therapeutics, Inc. (LRMR) filed an 8-K reporting results of its virtual 2026 Annual Meeting of Stockholders held May 19, 2026. As of the March 25, 2026 record date, 103,882,937 shares of common stock were outstanding and entitled to vote.
• The company re-elected three Class III directors — Frank Thomas, Carole S. Ben‑Maimon, M.D., and Joseph Truitt — to serve until the 2029 annual meeting. It also approved an amendment to increase authorized common shares from 115,000,000 to 215,000,000 and ratified PricewaterhouseCoopers LLP as independent auditors for 2026.

Key Details

• Outstanding shares at record date: 103,882,937.
• Director vote totals (for / withheld / broker non-votes):
  • Frank Thomas: 66,827,378 for; 8,569,298 withheld; 15,489,254 broker non-votes.
  • Carole S. Ben‑Maimon, M.D.: 67,314,208 for; 8,082,468 withheld; 15,489,254 broker non-votes.
  • Joseph Truitt: 66,445,617 for; 8,951,059 withheld; 15,489,254 broker non-votes.
• Say-on-pay (advisory) approved: 73,822,237 for; 1,498,429 against; 76,010 abstentions; 15,489,254 broker non-votes.
• Advisory vote on frequency favored annual votes: 72,645,858 for "every year".
• Authorized common shares approved to increase from 115,000,000 to 215,000,000 (89,732,486 for; 1,046,555 against; 106,889 abstentions).
• PwC ratified as independent registered public accounting firm for 2026 (90,784,651 for).

Why It Matters

• Board continuity: Re-election of the three Class III directors maintains current leadership through 2029, which matters for strategy and oversight.
• Share count increase: Approval to raise authorized common shares to 215 million gives the company flexibility to issue additional stock for financing, equity compensation, or strategic purposes — a decision that can affect dilution and capital strategy.
• Governance signals: Stockholders supported the company’s 2025 executive compensation on an advisory basis and opted for annual "say-on-pay" votes going forward, reflecting investor preference for regular compensation review.
• Audit ratification: Re-appointing PwC confirms continuity in the company’s external audit oversight for fiscal 2026.

Keywords: annual meeting, elects directors, authorized shares increase, say-on-pay, audit ratification, Larimar Therapeutics.